NTLA vs. CLDX, NEOG, MYGN, QDEL, EDIT, CLLS, SGMO, CRSP, LNTH, and RXST
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Celldex Therapeutics (CLDX), Neogen (NEOG), Myriad Genetics (MYGN), QuidelOrtho (QDEL), Editas Medicine (EDIT), Cellectis (CLLS), Sangamo Therapeutics (SGMO), CRISPR Therapeutics (CRSP), Lantheus (LNTH), and RxSight (RXST). These companies are all part of the "medical" sector.
Intellia Therapeutics (NASDAQ:NTLA) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
Intellia Therapeutics presently has a consensus price target of $66.77, indicating a potential upside of 172.97%. Celldex Therapeutics has a consensus price target of $66.00, indicating a potential upside of 65.33%. Given Intellia Therapeutics' higher probable upside, research analysts clearly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.
In the previous week, Celldex Therapeutics had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 21 mentions for Celldex Therapeutics and 17 mentions for Intellia Therapeutics. Celldex Therapeutics' average media sentiment score of 0.60 beat Intellia Therapeutics' score of 0.53 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Celldex Therapeutics received 180 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 74.88% of users gave Celldex Therapeutics an outperform vote while only 69.49% of users gave Intellia Therapeutics an outperform vote.
88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.0% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.7% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Intellia Therapeutics has a net margin of -893.34% compared to Celldex Therapeutics' net margin of -2,054.46%. Celldex Therapeutics' return on equity of -41.06% beat Intellia Therapeutics' return on equity.
Celldex Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.
Summary
Celldex Therapeutics beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
